Conjugates of amphotericin B to resolve challenges associated with its delivery-Reference-Cited by-同舟云学术

Conjugates of amphotericin B to resolve challenges associated with its delivery

Published:2024-01-31 Issue:2 Volume:21 Page:187-210
ISSN:1742-5247
Container-title:Expert Opinion on Drug Delivery
language:en
Short-container-title:Expert Opinion on Drug Delivery

Author:

Jain Vineet Kumar¹,Jain Keerti²,Popli Harvinder¹

Affiliation:

1. Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi, India

2. Drug Delivery and Nanomedicine Research Laboratory, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) – Raebareli, Lucknow, India

Funder

Indian Council of Medical Research

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425247.2024.2308073

Reference107 articles.

1. Delivery strategies of amphotericin B for invasive fungal infections

2. Solid lipid nanoparticles of amphotericin B (AmbiOnp): in vitro and in vivo assessment towards safe and effective oral treatment module

3. Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

4. Difficulties in antifungal therapy with amphotericin B and the continuous search for new formulations: A literature review

5. Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Amphotericin B Decorated Gold Nanoparticles as a Promising Antileishmanial Nanoconjugate;ACS Applied Bio Materials;2024-08-18

2. Advanced Application of Polymer Nanocarriers in Delivery of Active Ingredients from Traditional Chinese Medicines;Molecules;2024-07-26

3. Advances in nanotechnology for improving the targeted delivery and activity of amphotericin B (2011–2023): a systematic review;Nanotoxicology;2024-04-02

4. Novel Technologies in PROTAC Design;PROTAC-Mediated Protein Degradation: A Paradigm Shift in Cancer Therapeutics;2024